Precision Brain Health Research Act of 2025
Summary
S. 800 (Precision Brain Health Research Act of 2025) expands the VA's biomarker research mandate but authorizes zero new funding. The bill is reported out of committee and awaiting floor action. Labcorp ($LH at $262.63) and Quest Diagnostics ($DGX at $194.98) show no legislative catalyst in their recent price trends—both are down ~0.5-1.6% over the last 30 days. No near-term market impact.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S. 800 expands VA biomarker research but authorizes ZERO new funding—it is a mandate bill, not a spending bill.
- 2.Labcorp ($LH) and Quest Diagnostics ($DGX) show no price reaction to this legislation; both are down ~0.5-1.6% in the last 30 days.
- 3.Any revenue for diagnostic service providers requires a separate appropriations bill—likely not before FY2028 at the earliest.
- 4.The bill is awaiting Senate floor action; current legislative momentum is low with only 3 cosponsors.
Market Implications
Labcorp ($LH at $262.63) and Quest Diagnostics ($DGX at $194.98) are not moving on this bill. The 30-day price declines of -1.57% and -0.51% respectively indicate no legislative catalyst. This is correct pricing behavior—the bill authorizes zero dollars. Investors should not expect any contract revenue from this legislation until FY2028 appropriations are passed. The April 2026 executive order on psychedelic therapies is a separate policy track and should not be conflated with this bill's biomarker research mandate.
Full Analysis
-
WHAT HAPPENED AND STATUS: S. 800 was introduced February 27, 2025 by Sen. Moran (R-KS) with 3 cosponsors. It had hearings May 21, 2025 and was ordered reported favorably with an amendment on July 30, 2025. As of the enrichment data, it is awaiting floor action. The bill amends the Scott Hannon Initiative to add repetitive low-level blast exposure, dementia, and other brain conditions to the VA's biomarker research mandate. It also requires a data-sharing partnership between VA and DoD.
-
MONEY TRAIL — AUTHORIZATION vs APPROPRIATION: This bill explicitly authorizes zero new funding. It is a mandate-only bill—it tells the VA to expand research but provides no new budget authority. Any actual contract spending for diagnostic services from Labcorp or Quest would require a separate appropriations bill. The April 2026 executive order on psychedelic therapies is structurally separate and not relevant to this bill's funding mechanism.
-
STRUCTURAL WINNERS AND LOSERS: No current winners. The bill is a legislative placeholder. If future appropriations follow, Labcorp ($LH) and Quest Diagnostics ($DGX) are the most likely beneficiaries as diagnostic service providers. The VA already contracts with both companies for lab testing. However, no contract solicitation exists, no funding exists, and the bill hasn't passed the Senate floor.
-
REAL MARKET DATA ANALYSIS: Labcorp ($LH) closed at $262.63 on 4/30/2026, down -0.44% in 7 days and -1.57% in 30 days. Recent price action shows a decline from $270.68 on 4/17 to $262.63 on 4/30—consistent with broad market movement, not a legislative catalyst. Quest Diagnostics ($DGX) closed at $194.98, down -0.66% in 7 days and -0.51% in 30 days. Neither stock shows any spike corresponding to the bill's July 2025 committee action or any other milestone. This confirms the market is pricing in zero probability of near-term revenue.
-
TIMELINE: The bill is on the Senate calendar awaiting floor action. With 3 cosponsors and a Republican lead sponsor, passage is possible but not imminent. If passed, the bill still requires appropriations before any market impact occurs—that's a separate legislative process in the 2027 (FY2028) budget cycle at the earliest.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Expanded biomarker research mandate at VA for low-level blast exposure, dementia, and other brain conditions; requires identification and validation of biomarkers; authorizes zero new funding.
Who must act
Department of Veterans Affairs (VA) and Department of Defense (DoD) under a new data-sharing partnership.
What happens
VA must expand its biomarker research program scope but has no new appropriations to fund external contracts; any future diagnostic service contracts would require separate appropriations legislation.
Stock impact
Labcorp could be a future vendor for biomarker testing services if VA appropriates funds, but with no funding authorized and the bill awaiting floor action, there is zero near-term revenue visibility for Labcorp's diagnostic services segment.
What the bill does
Same expanded biomarker research mandate at VA; potential future contract opportunities for diagnostic testing services, but no funding mechanism.
Who must act
Department of Veterans Affairs (VA).
What happens
VA research expansion creates a potential procurement need for biomarker testing, but without appropriations it is a legislative authorization only—no contract dollars obligated.
Stock impact
Quest Diagnostics could compete for VA testing contracts, but with no funding authorized and the bill stalled at committee report stage, there is no current or near-term revenue impact for Quest's government diagnostic services business.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
SUPPORT for Patients and Communities Reauthorization Act of 2025
ASAP Act
CHOICE for Veterans Act of 2025
Supporting Healthy Moms and Babies Act
Reducing Hereditary Cancer Act
Thyroid Disease CARE Act of 2025
Increasing Access to Lung Cancer Screening Act
Access to Breast Cancer Diagnosis Act of 2025
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Presidential Determination Pursuant to Section 101 of the Defense Production Act of 1950, as Amended, on Recoverable Critical Minerals and Materials
This memorandum invokes the Defense Production Act (DPA) Section 101 to declare that recoverable critical minerals and materials (such as black mass, end-of-life rare-earth magnets, and scrap) are essential to national defense and that the U.S. cannot meet defense needs without disrupting civilian markets. It directs the Secretary of Commerce to issue regulations and take actions—including priority contracts and supply-chain interventions—to rapidly expand domestic recovery and processing of these materials, while explicitly excluding copper scrap already covered by a separate proclamation.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →